RxDoctor Payments Data

Joseph Califano, MD

Interventional Cardiology · Naples, FLNPI 1467404749

Payments from drug & device makers

$1,429in general payments, 2019–2025

Across 46 payments — averaging $31.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$428
  • Inari Medical, Inc.$323
  • Cardiva Medical, Inc.$107
  • Alnylam Pharmaceuticals Inc.$97
  • Stryker$97
  • Medtronic$67
  • plus $310 from 13 others

What the payments were for

  • Food & beverage$1,41599%
  • Education$141%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,429 in reported general payments places this provider in the 10th percentile of 623 interventional cardiology providers in Florida.

See all interventional cardiology providers in Florida

Medicare billing

Part B allowed, 2024
$533,335
Medicare patients
1,106
Services billed
5,698

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan206$323,130
XareltoRivaroxaban234$318,816
EliquisApixaban185$259,184
Repatha SureclickEvolocumab101$129,404
MounjaroTirzepatide81$98,934
OzempicSemaglutide60$72,719
BrilintaTicagrelor46$46,356
Prasugrel Hcl356$38,291
Praluent PenAlirocumab23$24,454
Ezetimibe886$22,368
JardianceEmpagliflozin13$21,512
NexlizetBempedoic Acid/Ezetimibe15$17,192
Rosuvastatin Calcium1,281$16,922
LivaloPitavastatin Calcium16$15,339
Metoprolol Succinate764$11,890

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$23$318,816234 claims
Novo NordiskOzempic$36$72,71960 claims
AstraZenecaBrilinta$14$46,35646 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 10th percentile of 623 interventional cardiology providers in Florida.

Other interventional cardiology in Naples

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →